NEWSIGHT
21.10.2021 15:52:04 CEST | Business Wire | Press release
Newsight Imaging Ltd., an innovative semiconductor company developing machine vision sensors, spectral vision chips and systems, announces a commercial agreement with SSZN. SSZN is a leader in developing smart industry 4.0 solutions for supporting automated production line supervision. Newsight will provide SSZN with the NSI1000 - its new and advanced sensor chip.
The deal follows a successful design-win where SSZN conducted an evaluation using the NSI1000 chip, closely supported by Newsight's engineering teams in Israel and Shenzhen. The first order of 100,000 chips will be supplied in the upcoming months.
The NSI1000 CMOS Image sensor chip, launched by Newsight last year, consists of 32 lines of 1024 pixels and it supports multiple modes, such as multi-triangulation for state-of-the-art accuracy and fast operation on production line inspection. The sensor implements Newsight's enhanced Time of Flight (eTOF™) technology for advanced, long-range, and high-resolution 3D depth image capturing. SSZN integrates the chip into its advanced industrial sensor lines, which serve SSZN’s major customers.
“SSZN is committed to providing high-performance industrial inspection automation, as we dedicate our efforts to streamlining customer operations worldwide. Our cutting-edge technology provides highly integrated solutions for production supervision, enabling real time monitoring and maneuverability for any manufacturing process. Following our evaluation, we are pleased to have chosen Newsight’s image sensors upon proving their high quality and performance”, said Mr. GK Wang, CEO of SSZN.
“We are very pleased to collaborate with SSZN" says Mr. Eli Assoolin, CEO and Chairperson of Newsight Imaging Ltd. "Being chosen by such an important industry 4.0 player further highlights Newsight's product performance and customer value. Our disruptive sensor is embedded with unique features to support the extensive demands of smart manufacturing. We are currently running numerous evaluations with lead players, already marking several design-wins. Our upcoming NSI9000 sensor chip, with a 1024x480 depth resolution, will undoubtedly be a game changer for various industries, such as the automotive and smart manufacturing industries".
About SSZN
The company’s solution is widely implemented in various industries, including: 3C, traditional manufacturing, new energy power battery, mechanical processing procedure inspection, electrical testing and others. The company has partnered with customers such as Foxconn, BYD, Lite-On, Huawei, Daheng, Tongda and Han's Laser, and has led to significantly reduced manufacturing costs, improved product quality and optimized efficiency.
About Newsight
Newsight develops advanced CMOS image sensor chips for 3D machine vision and spectral analysis. Newsight’s depth camera sensors for machine vision serve verticals such as Mobile, Robotics, Industry 4.0, Automotive Safety etc. The company has recently launched its one-of-a-kind solid-state LiDAR reference design, the eTOF™ LiDAR – based on the NSI1000 sensor. The company has US and EU patents and has received 3 grants by the Israeli Innovation Authority.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005678/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Together AI and HUMAIN Form Strategic Partnership to Accelerate AI Infrastructure and Cloud Services in Saudi Arabia31.8.2026 14:00:00 CEST | Press release
The partnership, which was announced on stage at LEAP, Combines HUMAIN’s AI Infrastructure Foundation with Together’s AI Native Cloud Platform and Global Reach Together AI, a leading San Francisco-based AI Native Cloud platform, and HUMAIN, a PIF company delivering full-stack artificial intelligence capabilities globally, today at LEAP announced a strategic partnership to connect HUMAIN’s rapidly expanding AI compute capacity in Saudi Arabia with global AI-native and enterprise demand. The partnership will include the construction of a new 250 megawatt data center, located in Saudi Arabia. The partnership brings together HUMAIN’s large-scale, multi-chip AI infrastructure footprint, expanding cloud and inference capabilities with Together AI’s global customer ecosystem and AI-native inference platform. Together, the companies will offer an additional option for developers, enterprises, and AI-native organizations worldwide to access high-performance AI infrastructure for inference and t
SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 12:50:00 CEST | Press release
Scalable, energy-efficient and reliable thermal management technologies will optimize operating performance in increasingly complex data centers and industrial systems SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions,
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
